Ruxolitinib combined with azithromycin for scrub typhus-associated hemophagocytic lymphohistiocytosis in a child: a case report and narrative literature review - Scorecard - MDSpire
Advertisement
Ruxolitinib combined with azithromycin for scrub typhus-associated hemophagocytic lymphohistiocytosis in a child: a case report and narrative literature review
Clinical Scorecard: Combination of Ruxolitinib and Azithromycin for Treating Hemophagocytic Lymphohistiocytosis Linked to Scrub Typhus in a Pediatric Patient: A Case Study and Literature Overview
At a Glance
Category
Detail
Condition
Key Mechanisms
JAK1/2 inhibition targeting the interferon-gamma pathway (source needed)
Target Population
Care Setting
Pediatric clinical care (source needed)
Key Highlights
First report of ruxolitinib in scrub typhus-associated HLH (source needed)
Mortality rate of scrub typhus-associated HLH reported at 11.9%–30% (source needed)
Absence or delay of anti-rickettsial therapy linked to poor outcomes (source needed)
Guideline-Based Recommendations
Diagnosis
Management
First-line treatment includes doxycycline for scrub typhus; azithromycin as an alternative (source needed)
Immunomodulation with corticosteroids and IVIG is common (source needed)
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Pediatric patients with confirmed scrub typhus infection
Ruxolitinib (5 mg twice daily) and azithromycin (10 mg/kg once daily) led to rapid resolution of symptoms
Clinical Best Practices
Consider JAK1/2 inhibitors in severe cases of HLH (source needed)
